AYUSH and Alternative Medicine News

Related Pharmaceuticals Industry News

• June 2022: Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. announced strategic cooperation to develop, manufacture, and commercialize Liraglutide (including both indications of diabetes and obesity) in 17 countries in the Middle East and North Africa region (MENA) including the UAE.
• May 2022: The US FDA approved Eli Lilly and Company’s Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

• October 2022: Zimbabwe approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention.
• October 2022: China handed a state-of-the-art pharmaceutical warehouse to the Zimbabwean government, which is expected to boost Zimbabwe's drug storage capacity and improve its health delivery system.

• October 2022: Alvotech and the JAMP Pharma Group (a Canadian pharmaceutical company) announced the expansion of their exclusive partnership to commercialize biosimilars (AVT16 & AVT33) developed and manufactured by Alvotech.
• May 2022: Biocon Biologics and Viatris (formerly Mylan) launched the cancer drug bevacizumab under the brand name Abevmy in Canada.
• April 2022: AMP Pharma Group, a Canadian-owned pharmaceutical company, announced the launch of SIMLANDI, a high-concentration, low-volume, citrate-free biosimilar to Humira (adalimumab), developed and manufactured by Alvotech.
• January 2022: Pfizer Canada entered a three-year partnership with the Canadian Race Relations Foundation (CRRF) to conduct a series of dialogues on health equity and concerns affecting racialized communities' access to health and mental health services.
• January 2022: Eli Lilly and Company entered into a research and collaboration partnership with Entos Pharmaceuticals in Canada. This deal will support the development of therapies for multiple neurological disorders.

• December 2022: Roche reported the launch of a drug for a rare autoimmune disorder, neuromyelitis optica spectrum disorder (NMOSD), in India by the end of 2023. This drug is focused on precision medicine.
• November 2022: BGI Genomics and the University of Pécs (UP) agreed to launch a joint laboratory in Hungary. The joint lab is to start official operations to accelerate the development of genomic sequencing and clinical diagnostic services while strengthening BGI Genomics and the UP's innovative precision medicine developments in the Central and Eastern European region.

• In August 2022, Glenmark Pharmaceuticals’ arm has launched the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the United States market.
• In March 2022, Perrigo Company plc announced that it has received final approval from the US FDA for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).

• In November 2022, Glenmark Pharmaceuticals received approval from the US health regulator to market sodium phenylbutyrate tablets, used in treating urea cycle disorders, in America.
• In October 2022, Glenmark's United States-based unit launched generic Fingolimod capsules, used to treat multiple sclerosis, in the American market.

• In March 2022, Galderma Launched TWYNEO Cream in the United States to treat facial acne at the American Academy of Dermatology Annual Meeting, which is commercially available in spring.
• In January 2022, Journey Medical Corporation acquired two Food and Drug Administration-approved topical minocycline products and the molecule Stabilizing Technology (MST) Franchise from VYNE Therapeutics, Inc. This franchise includes AMZEEQ for the treatment of acne.

• October 2021- Otsuka received approval for an additional pediatric indication in Europe. Otsuka has been working on expanding access to DELTYBA worldwide in support of that effort.
• October 2021- Sandoz, a Novartis division, acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands (Zinnat, Zinacef, and Fortum) in more than 100 markets, strengthening its position as the world's leading antibiotics company.

• October 2022: Leo Pharma launched a campaign to raise awareness of atopic dermatitis across cultures. This campaign featured the journey of four patients from France, Italy, Germany, and Spain living with chronic skin disease.
• June 2022: Sanofi received USFDA approval for Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

• August 2022: Allergan Healthcare India launched Juvéderm VOLUX, an injectable implant intended to restore and create the volume of the face, under its Business Unit of Allergan Aesthetics.
• February 2022: Merz Aesthetics launched Radiesse (+) as the first and only aesthetic injectable to improve moderate to severe loss of jawline contour.